{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:16:38Z","timestamp":1792192598435,"version":"4.4.0"},"reference-count":52,"publisher":"Bioscientifica","issue":"12","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based study examined 112,256 patients with neuroendocrine tumors between 2000 and 2018 using data from the Surveillance, Epidemiology, and End Results program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The age-adjusted incidence per 100,000 persons of neuroendocrine tumors increased from 4.90 in 2000 to 8.19 in 2018 (annual percentage change, 3.40; 95% confidence interval, 3.13\u20133.67), with the most significant increases in grade 1, localized stage, and appendix neuroendocrine tumors. The age-adjusted mortality rate increased 3.1-fold from 2000 to 2018 (annual percentage change, 4.14; 95% confidence interval, 3.14\u20135.15). The 1-, 5-, and 10-year relative survival rates for all neuroendocrine tumors were 80.5%, 68.4%, and 63.5%, respectively. Multivariate analyses showed that male sex; older age; Black, American Indian, and Alaska Native populations; earlier year of diagnosis; lung neuroendocrine tumors; higher grades; and later stage were associated with a worse prognosis and that disease stage and grade were the most important risk factors for prognosis. Furthermore, we established a nomogram to predict the 3-, 5-, and 10-year survival rates, and its discrimination ability was better than that of the TNM classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence, prevalence, and mortality rate of neuroendocrine tumors continued to increase over the last two decades. Additionally, the nomogram could accurately quantify the risk of death in patients with neuroendocrine tumors and had good clinical practicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-23-0331","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:17:32Z","timestamp":1698668252000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":40,"title":["Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA"],"prefix":"10.1530","volume":"12","author":[{"given":"Peiwen","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tangdu Hospital, the Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tangdu Hospital, the Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-2181","authenticated-orcid":true,"given":"Xiaozhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"JAMA Oncology","first-page":"1335","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","unstructured":"Dasari AShen CHalperin DZhao BZhou SXu YShih T & Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology201731335\u20131342. (https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589)"},{"key":"bib2","series-title":"Lancet Oncology","first-page":"61","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","unstructured":"Modlin IMOberg KChung DCJensen RTHerder de WWThakker RVCaplin MDelle Fave GKaltsas GAKrenning EP, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology2008961\u201372. (https:\/\/doi.org\/10.1016\/S1470-2045(0770410-2)"},{"key":"bib3","series-title":"Neoplasia (New York, NY)","first-page":"991","article-title":"Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas","volume":"19","author":"Oronsky","year":"2017","unstructured":"Oronsky BMa PCMorgensztern D & Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia (New York, NY)201719991\u20131002. (https:\/\/doi.org\/10.1016\/j.neo.2017.09.002)"},{"key":"bib4","series-title":"Journal of Clinical Oncology","first-page":"3063","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","unstructured":"Yao JCHassan MPhan ADagohoy CLeary CMares JEAbdalla EKFleming JBVauthey JNRashid A, et al. One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology2008263063\u20133072. (https:\/\/doi.org\/10.1200\/JCO.2007.15.4377)"},{"key":"bib5","series-title":"Cancer","first-page":"589","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","unstructured":"Hallet JLaw CHLCukier MSaskin RLiu N & Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer2015121589\u2013597. (https:\/\/doi.org\/10.1002\/cncr.29099)"},{"key":"bib6","series-title":"CA","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","unstructured":"Cives M & Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA201868471\u2013487. (https:\/\/doi.org\/10.3322\/caac.21493)"},{"key":"bib7","series-title":"Journal of Patient Safety","first-page":"52","article-title":"Trends in computed tomography utilization rates: a longitudinal practice-based study","volume":"10","author":"Hess","year":"2014","unstructured":"Hess EPHaas LRShah NDStroebel RJDenham CR & Swensen SJ. Trends in computed tomography utilization rates: a longitudinal practice-based study. Journal of Patient Safety20141052\u201358. (https:\/\/doi.org\/10.1097\/PTS.0b013e3182948b1a)"},{"key":"bib8","series-title":"Annals of Biomedical Engineering","first-page":"260","article-title":"Recent and future directions in CT imaging","volume":"42","author":"Pelc","year":"2014","unstructured":"Pelc NJ. Recent and future directions in CT imaging. Annals of Biomedical Engineering201442260\u2013268. (https:\/\/doi.org\/10.1007\/s10439-014-0974-z)"},{"key":"bib9","series-title":"Virchows Archiv","first-page":"395","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","unstructured":"Rindi GKl\u00f6ppel GAlhman HCaplin MCouvelard AHerder de WWErikssson BFalchetti AFalconi MKomminoth P, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv2006449395\u2013401. (https:\/\/doi.org\/10.1007\/s00428-006-0250-1)"},{"key":"bib10","series-title":"Virchows Archiv","first-page":"757","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","unstructured":"Rindi GKl\u00f6ppel GCouvelard AKomminoth PK\u00f6rner MLopes JMMcNicol AMNilsson OPerren AScarpa A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv2007451757\u2013762. (https:\/\/doi.org\/10.1007\/s00428-007-0452-1)"},{"key":"bib11","series-title":"Pancreas","first-page":"707","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","unstructured":"Klimstra DSModlin IRCoppola DLloyd RV & Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas201039707\u2013712. (https:\/\/doi.org\/10.1097\/MPA.0b013e3181ec124e)"},{"key":"bib12","series-title":"CA","first-page":"180","article-title":"The staging of cancer: a retrospective and prospective appraisal","volume":"58","author":"Greene","year":"2008","unstructured":"Greene FL & Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA200858180\u2013190. (https:\/\/doi.org\/10.3322\/CA.2008.0001)"},{"key":"bib13","series-title":"JAMA Network Open","first-page":"e2124750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","unstructured":"Xu ZWang LDai SChen MLi FSun J & Luo F. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Network Open20214e2124750. (https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24750)"},{"key":"bib14","series-title":"British Journal of Cancer","first-page":"1544","article-title":"Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms","volume":"117","author":"Fang","year":"2017","unstructured":"Fang CWang WFeng XSun JZhang YZeng YWang JChen HCai MLin J, et al. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer20171171544\u20131550. (https:\/\/doi.org\/10.1038\/bjc.2017.315)"},{"key":"bib15","series-title":"ESMO Open","first-page":"e000632","article-title":"Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis","volume":"5","author":"Li","year":"2020","unstructured":"Li JLin YWang YLin HLin FZhuang QLin X & Wu J. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. ESMO Open20205e000632. (https:\/\/doi.org\/10.1136\/esmoopen-2019-000632)"},{"key":"bib16","series-title":"British Journal of Surgery","first-page":"226","article-title":"Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria","volume":"103","author":"Sandvik","year":"2016","unstructured":"Sandvik OMS\u00f8reide KGudlaugsson EKval\u00f8y JT & S\u00f8reide JA. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. British Journal of Surgery2016103226\u2013232. (https:\/\/doi.org\/10.1002\/bjs.10034)"},{"key":"bib17","series-title":"JAMA Network Open","first-page":"e2137508","article-title":"Association of stage shift and population mortality among patients with non-small cell lung cancer","volume":"4","author":"Flores","year":"2021","unstructured":"Flores RPatel PAlpert NPyenson B & Taioli E. Association of stage shift and population mortality among patients with non-small cell lung cancer. JAMA Network Open20214e2137508. (https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.37508)"},{"key":"bib18","series-title":"JAMA","first-page":"1338","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013","volume":"317","author":"Lim","year":"2017","unstructured":"Lim HDevesa SSSosa JACheck D & Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013. JAMA20173171338\u20131348. (https:\/\/doi.org\/10.1001\/jama.2017.2719)"},{"key":"bib19","series-title":"Cancer Medicine","first-page":"6318","article-title":"Survival trends for patients with retinoblastoma between 2000 and 2018: what has changed?","volume":"12","author":"Abdelazeem","year":"2023","unstructured":"Abdelazeem BAbbas KSShehata JEl-Shahat NAEltaras MMQaddoumi I & Alfaar AS. Survival trends for patients with retinoblastoma between 2000 and 2018: what has changed?Cancer Medicine2023126318\u20136324. (https:\/\/doi.org\/10.1002\/cam4.5406)"},{"key":"bib20","series-title":"BMC Cancer","first-page":"830","article-title":"Racial differences in 5-year relative survival rates of cervical cancer by stage at diagnosis, between African American (black) and white women, living in the state of Alabama, USA","volume":"20","author":"Abdalla","year":"2020","unstructured":"Abdalla ETroy RFall SElhussin IEgiebor-Aiwan O & Nganwa D. Racial differences in 5-year relative survival rates of cervical cancer by stage at diagnosis, between African American (black) and white women, living in the state of Alabama, USA. BMC Cancer202020830. (https:\/\/doi.org\/10.1186\/s12885-020-07338-7)"},{"key":"bib21","series-title":"Statistics in Medicine","first-page":"3670","article-title":"Estimating average annual per cent change in trend analysis","volume":"28","author":"Clegg","year":"2009","unstructured":"Clegg LXHankey BFTiwari RFeuer EJ & Edwards BK. Estimating average annual per cent change in trend analysis. Statistics in Medicine2009283670\u20133682. (https:\/\/doi.org\/10.1002\/sim.3733)"},{"key":"bib22","series-title":"Journal of the Royal Statistical Society. Series A,","first-page":"405","article-title":"Modelling population-based cancer survival trends using join point models for grouped survival data","volume":"172","author":"Yu","year":"2009","unstructured":"Yu BHuang LTiwari RCFeuer EJ & Johnson KA. Modelling population-based cancer survival trends using join point models for grouped survival data. Journal of the Royal Statistical Society. Series A,2009172405\u2013425. (https:\/\/doi.org\/10.1111\/j.1467-985X.2009.00580.x)"},{"key":"bib23","series-title":"British Journal of Cancer","first-page":"966","article-title":"Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013\u20132015","volume":"121","author":"Genus","year":"2019","unstructured":"Genus TSEBouvier CWong KFSrirajaskanthan RRous BATalbot DCValle JWKhan MPearce NElshafie M, et al. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013\u20132015. British Journal of Cancer2019121966\u2013972. (https:\/\/doi.org\/10.1038\/s41416-019-0606-3)"},{"key":"bib24","series-title":"Endocrine, Metabolic and Immune Disorders Drug Targets","first-page":"448","article-title":"A retrospective cohort study of histology-proven neuroendocrine neoplasms in the Italian area of Udine","volume":"21","author":"Valent","year":"2021","unstructured":"Valent FTullio AKara ECipri CSciannimanico SMVescini F & Grimaldi F. A retrospective cohort study of histology-proven neuroendocrine neoplasms in the Italian area of Udine. Endocrine, Metabolic and Immune Disorders Drug Targets202121448\u2013457. (https:\/\/doi.org\/10.2174\/1871530320666200713093533)"},{"key":"bib25","series-title":"Chinese Medical Journal","first-page":"1216","article-title":"Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States","volume":"136","author":"Zheng","year":"2023","unstructured":"Zheng RZhao HAn LZhang SChen RWang SSun KZeng HWei W & He J. Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States. Chinese Medical Journal20231361216\u20131224. (https:\/\/doi.org\/10.1097\/CM9.0000000000002643)"},{"key":"bib26","series-title":"European Journal of Cancer","first-page":"80","article-title":"The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms","volume":"168","author":"Borbath","year":"2022","unstructured":"Borbath IGarcia-Carbonero RBikmukhametov DJimenez-Fonseca PCasta\u00f1o ABarkmanova JSedlackova EKoll\u00e1r AChrist EKaltsas G, et al. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European Journal of Cancer202216880\u201390. (https:\/\/doi.org\/10.1016\/j.ejca.2022.03.007)"},{"key":"bib27","series-title":"BMC Cancer","first-page":"1104","article-title":"Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study","volume":"20","author":"Masui","year":"2020","unstructured":"Masui TIto TKomoto IUemoto S & JNETS Project Study Group. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer2020201104. (https:\/\/doi.org\/10.1186\/s12885-020-07581-y)"},{"key":"bib28","series-title":"Oncotarget","first-page":"71699","article-title":"A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china","volume":"8","author":"Fan","year":"2017","unstructured":"Fan JHZhang YQShi SSChen YJYuan XHJiang LMWang SMMa LHe YTFeng CY, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget2017871699\u201371708. (https:\/\/doi.org\/10.18632\/oncotarget.17599)"},{"key":"bib29","series-title":"Cancer Epidemiology","first-page":"101598","article-title":"Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia","volume":"63","author":"Wyld","year":"2019","unstructured":"Wyld DWan MHMoore JDunn N & Youl P. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiology201963101598. (https:\/\/doi.org\/10.1016\/j.canep.2019.101598)"},{"key":"bib30","series-title":"Current Oncology Reports","first-page":"43","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","unstructured":"Das S & Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?Current Oncology Reports20212343. (https:\/\/doi.org\/10.1007\/s11912-021-01029-7)"},{"key":"bib31","series-title":"International Journal of Cancer","first-page":"2679","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki MHemminki ASundquist KSundquist J & Hemminki K. The epidemiology of metastases in neuroendocrine tumors. International Journal of Cancer20161392679\u20132686. (https:\/\/doi.org\/10.1002\/ijc.30400)"},{"key":"bib32","series-title":"Cancer Research and Treatment","first-page":"157","article-title":"Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000\u20132009: Multicenter Study","volume":"44","author":"Cho","year":"2012","unstructured":"Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MYKim JMSohn JHKim MJKim KMKim WHKim HKook MCPark DY, et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000\u20132009: Multicenter Study. Cancer Research and Treatment201244157\u2013165. (https:\/\/doi.org\/10.4143\/crt.2012.44.3.157)"},{"key":"bib33","series-title":"Endocrine-Related Cancer","first-page":"R153","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","unstructured":"Fraenkel MKim MFaggiano AHerder de WWValk GD & Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocrine-Related Cancer201421R153\u2013R163. (https:\/\/doi.org\/10.1530\/ERC-13-0125)"},{"key":"bib34","series-title":"New England Journal of Medicine","first-page":"125","article-title":"Phase 3 trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","unstructured":"Strosberg JEl-Haddad GWolin EHendifar AYao JChasen BMittra EKunz PLKulke MHJacene H, et al. Phase 3 trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine2017376125\u2013135. (https:\/\/doi.org\/10.1056\/NEJMoa1607427)"},{"key":"bib35","series-title":"Journal of Clinical Oncology","first-page":"2124","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJHerder de WWKam BLEijck van CHEssen van MKooij PPFeelders RAAken van MO & Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology2008262124\u20132130. (https:\/\/doi.org\/10.1200\/JCO.2007.15.2553)"},{"key":"bib36","series-title":"Lancet. Oncology","first-page":"1500","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","unstructured":"Xu JShen LZhou ZLi JBai CChi YLi ZXu NLi ELiu T, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. Oncology2020211500\u20131512. (https:\/\/doi.org\/10.1016\/S1470-2045(2030496-4)"},{"key":"bib37","series-title":"Lancet. Oncology","first-page":"1489","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","unstructured":"Xu JShen LBai CWang WLi JYu XLi ZLi EYuan XChi Y, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. Oncology2020211489\u20131499. (https:\/\/doi.org\/10.1016\/S1470-2045(2030493-9)"},{"key":"bib38","series-title":"Clinical Cancer Research","first-page":"3486","article-title":"Surufatinib in advanced well-differentiated neuroendocrine tumors: A multicenter, Single-Arm, Open-Label, Phase Ib\/II Trial","volume":"25","author":"Xu","year":"2019","unstructured":"Xu JLi JBai CXu NZhou ZLi ZZhou CJia RLu MCheng Y, et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: A multicenter, Single-Arm, Open-Label, Phase Ib\/II Trial. Clinical Cancer Research2019253486\u20133494. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2994)"},{"key":"bib39","series-title":"Alimentary Pharmacology and Therapeutics","first-page":"169","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","unstructured":"Modlin IMPavel MKidd M & Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology and Therapeutics201031169\u2013188. (https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04174.x)"},{"key":"bib40","series-title":"New England Journal of Medicine","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","unstructured":"Caplin MEPavel MCwikla JBPhan ATRaderer MSedlackova ECadiot GWolin EMCapdevila JWall L, et al.Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine2014371. (https:\/\/doi.org\/10.1056\/NEJMoa1316158)"},{"key":"bib41","series-title":"Journal of Clinical Oncology","first-page":"4656","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","unstructured":"Rinke AM\u00fcller HHSchade-Brittinger CKlose KJBarth PWied MMayer CAminossadati BPape UFBl\u00e4ker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology2009274656\u20134663. (https:\/\/doi.org\/10.1200\/JCO.2009.22.8510)"},{"key":"bib42","series-title":"Annals of Oncology","first-page":"844","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","unstructured":"Pavel M\u00d6berg KFalconi MKrenning EPSundin APerren ABerruti A & ESMO Guidelines Committee.Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology202031844\u2013860. (https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304)"},{"key":"bib43","series-title":"European Journal of Endocrinology","first-page":"R31","article-title":"GEP-NETs update: biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","unstructured":"Alonso-Gordoa TCapdevila J & Grande E. GEP-NETs update: biotherapy for neuroendocrine tumours. European Journal of Endocrinology2015172R31\u2013R46. (https:\/\/doi.org\/10.1530\/EJE-14-0354)"},{"key":"bib44","series-title":"Pancreas","first-page":"727","article-title":"Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study","volume":"50","author":"Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman O & Fazio N. Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study. Pancreas202150727\u2013731. (https:\/\/doi.org\/10.1097\/MPA.0000000000001821)"},{"key":"bib45","series-title":"Pancreas","first-page":"996","article-title":"Expression of estrogen-induced genes and estrogen receptor \u03b2 in pancreatic neuroendocrine tumors: implications for targeted therapy","volume":"43","author":"Estrella","year":"2014","unstructured":"Estrella JSMa LTMilton DRYao JCWang HRashid A & Broaddus RR. Expression of estrogen-induced genes and estrogen receptor \u03b2 in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas201443996\u20131002. (https:\/\/doi.org\/10.1097\/MPA.0000000000000203)"},{"key":"bib46","series-title":"Archives of Pathology and Laboratory Medicine","first-page":"1027","article-title":"Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors","volume":"138","author":"Estrella","year":"2014","unstructured":"Estrella JSBroaddus RRMathews AMilton DRYao JCWang H & Rashid A. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Archives of Pathology and Laboratory Medicine20141381027\u20131036. (https:\/\/doi.org\/10.5858\/arpa.2013-0195-OA)"},{"key":"bib47","series-title":"American Journal of Clinical Oncology","first-page":"668","article-title":"Competing mortality in patients with neuroendocrine tumors","volume":"42","author":"Low","year":"2019","unstructured":"Low SKGiannis DBahaie NSTrong BLHMoris D & Huy NT. Competing mortality in patients with neuroendocrine tumors. American Journal of Clinical Oncology201942668\u2013674. (https:\/\/doi.org\/10.1097\/COC.0000000000000575)"},{"key":"bib48","series-title":"Cancer Epidemiology","first-page":"641","article-title":"The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England","volume":"39","author":"Nur","year":"2015","unstructured":"Nur ULyratzopoulos GRachet B & Coleman MP. The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England. Cancer Epidemiology201539641\u2013649. (https:\/\/doi.org\/10.1016\/j.canep.2015.05.006)"},{"key":"bib49","series-title":"Cancer","first-page":"2655","article-title":"Neuroendocrine tumor epidemiology: contrasting Norway and North America","volume":"113","author":"Hauso","year":"2008","unstructured":"Hauso OGustafsson BIKidd MWaldum HLDrozdov IChan AKC & Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer20081132655\u20132664. (https:\/\/doi.org\/10.1002\/cncr.23883)"},{"key":"bib50","series-title":"Oncologist","first-page":"1123","article-title":"Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations","volume":"20","author":"Wolin","year":"2015","unstructured":"Wolin EM. Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung (typical and atypical carcinoid): current status and future considerations. Oncologist2015201123\u20131131. (https:\/\/doi.org\/10.1634\/theoncologist.2015-0198)"},{"key":"bib51","series-title":"Journal of Global Oncology","first-page":"43","article-title":"Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs","volume":"3","author":"Singh","year":"2017","unstructured":"Singh SGranberg DWolin EWarner RSissons MKolarova TGoldstein GPavel M\u00d6berg K & Leyden J. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. Journal of Global Oncology2017343\u201353. (https:\/\/doi.org\/10.1200\/JGO.2015.002980)"},{"key":"bib52","series-title":"Endocrine Reviews","first-page":"506","article-title":"Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms","volume":"40","author":"Mafficini","year":"2019","unstructured":"Mafficini A & Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocrine Reviews201940506\u2013536. (https:\/\/doi.org\/10.1210\/er.2018-00160)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/12\/EC-23-0331.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/12\/EC-23-0331.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/12\/EC-23-0331.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:51Z","timestamp":1784555211000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":52,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/ec-23-0331","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}